Dilsher Dhoot, MD, on a Promising Start With Diabetic Retinopathy Gene Therapy RGX-314

Commentary
Video

The adjunct clinical assistant professor, ophthalmology, Keck School of Medicine, University of Southern California discussed new data from the ALTITTUDE trial.

“There's still so many questions that remain, looking at long term gene expression and safety data is going to be key. I'm excited to see, at this higher dose level, how our patients do in terms of efficacy, and top line results also. So, I think there certainly still questions that remain. But you know, the data to date is very encouraging. And I really feel that this is one area in ophthalmology and retina that is very exciting.”

RGX-314 (REGENXBIO) gene therapy, delivered with a one-time suprachoroidal injection, was well-tolerated and yielded improvements in diabetic retinopathy severity scale (DRSS) scores in patients with DR treated in the phase 2 ALTITUDE trial (NCT04567550). Updated data from the study were presented by Dilsher S. Dhoot, MD, ophthalmologist, California Retina Consultants, and adjunct clinical assistant professor, ophthalmology, Keck School of Medicine, University of Southern California, at the American Society of Retina Specialists (ASRS) 2023 Annual Meeting, held July 29-August 1 in Seattle, Washington.

Dhoot presented positive preliminary findings which included no serious adverse events related to RGX-314, stable best-corrected visual acuity through 6 months, and improvements in DRSS, including a 2-step improvement in 20% of treated participants compared to 10% of control participants. Additionally, there were no cases of intraocular inflammation in a new cohort using an additional prophylactic steroid eye drop regimen.

CGTLive spoke with Dhoot to learn more about the data presented at ASRS. He went over the design of the study and the encouraging safety and efficacy findings observed.

REFERENCE
Dhoot DS. Suprachoroidal delivery of investigational ABBV-RGX-314 for diabetic retinopathy: The phase II ALTITUDE® study. Presented at: ASRS 2023 Annual Meeting, July 28-August 1; Seattle, Washington.
Related Videos
Akshay Sharma, MBBS, a bone marrow transplant physician at St. Jude Children’s Research Hospital
M. Peter Marinkovich, MD, on Bringing RDEB Treatment to the Local Level
Caspian Oliai, MD, MS, the medical director of the UCLA Bone Marrow Transplantation Stem Cell Processing Center
Frederick “Eric” Arnold, PhD
Genovefa (Zenia) Papanicolaou, MD, an infectious diseases specialist at Memorial Sloan Kettering Cancer Center
Jeffrey Chamberlain, PhD, on Exciting New Research at MDA 2024
Alan Beggs, PhD, on Challenges in Therapeutic Development for Rare Diseases
Akshay Sharma, MBBS, a bone marrow transplant physician at St. Jude Children’s Research Hospital
PJ Brooks, PhD
John DiPersio, MD, PhD, the director of the Center for Gene and Cellular Immunotherapy at Washington University School of Medicine
© 2024 MJH Life Sciences

All rights reserved.